Replies to post #26651 on Amarin Corp Plc (AMRN)

[RobinF]

Thank you, Jessellivermore. Correct me if wrong but isn't Reduce-it still underway while the appeal for re-instatement is in progress? I hate to sound morbid but what if in placebo group die now...and how many have to die for them to recognize that Vascepa is having an effect? It is sad that people need to die in order for the FDA to come to their senses!

[jessellivermore]

Less than 100 patients (Japanese) died out of 18,000 over a 5 year period..

Stop and think about it......that means on average 20 out of 18,000 middle aged patients all on low dose statins died each year; a little bit over one in a thousand. The biggest identifable difference between them and a similar group of Americans was their EPA/AA ratio...the LDL-C levels were similar. The risk in Americans was six times higher.

The REDUCE-IT trial is complicated by two factors. The first is the though the risk factors based on the selected population (cohort) is much higher than JELIS, and this favors the likelyhood of seeing benefits earlier in the trials, the REDUCE-IT patients are on higher doses of statins, and this has two significant effects. The first is statins probably exert whatever clinical benefit they provide by reducing systemic imflammation. One way to look at this is that statins could be considered "add ons" to EPA. We know at present that atherosclerosis is an inflammatory disease, and not a lipid disorder. Therefore the rational for any therapy should be directed toward reducing inflammation rather than lipids. The second statin effect concern is that statins tend to increase production of AA which counters the effects of EPA (V).

The realities are that science argument is very compelling, it is just not well known by clinicians, and it is being conviently ignored by the FDA. The chance of the statin cartel is behind alot of this is obvious.

":>)JL

[go seek]

Amarin has an approved product... with some demand and potentially blockbuster demand.

1. AMRN is not going to 'go under'.
2. Eventually the company will be bought out by a bigger player.
3. When and for how much?... that is yet to be determined.

Are shares inexpensive here? IMO yes.
But please do your own DD.

[stangish]

The biggest threat to V, is V itself./i]

IF reduce it is positive, the biggest threat is keeping the generics off the market. all the money spent on reduce it would be a waste to amarin if there are generics...

IMO.